These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 12544410)

  • 1. Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial.
    Gibb DM; Goodall RL; Giacomet V; McGee L; Compagnucci A; Lyall H;
    Pediatr Infect Dis J; 2003 Jan; 22(1):56-62. PubMed ID: 12544410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children.
    van Rossum AM; Bergshoeff AS; Fraaij PL; Hugen PW; Hartwig NG; Geelen SP; Wolfs TF; Weemaes CM; De Groot R; Burger DM
    Pediatr Infect Dis J; 2002 Aug; 21(8):743-7. PubMed ID: 12192162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection.
    Hoffmann F; Funk M; Linde R; Notheis G; Petropoulou T; Eberle J; Gürtler L; Belohradsky BH; Wintergerst U
    Eur J Med Res; 2002 Jul; 7(7):330-4. PubMed ID: 12176683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence to medication regimens among children with human immunodeficiency virus infection.
    Reddington C; Cohen J; Baldillo A; Toye M; Smith D; Kneut C; Demaria A; Bertolli J; Hsu HW
    Pediatr Infect Dis J; 2000 Dec; 19(12):1148-53. PubMed ID: 11144374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of plasma human immunodeficiency virus type 1 RNA response to highly active antiretroviral therapy in infected children.
    Spector SA; Hsia K; Yong FH; Cabral S; Fenton T; Fletcher CV; McNamara J; Mofenson LM; Starr SE
    J Infect Dis; 2000 Dec; 182(6):1769-73. PubMed ID: 11069252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection.
    Van Dyke RB; Lee S; Johnson GM; Wiznia A; Mohan K; Stanley K; Morse EV; Krogstad PA; Nachman S;
    Pediatrics; 2002 Apr; 109(4):e61. PubMed ID: 11927734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
    Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW;
    JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
    Walmsley S; Bernstein B; King M; Arribas J; Beall G; Ruane P; Johnson M; Johnson D; Lalonde R; Japour A; Brun S; Sun E;
    N Engl J Med; 2002 Jun; 346(26):2039-46. PubMed ID: 12087139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team.
    Starr SE; Fletcher CV; Spector SA; Yong FH; Fenton T; Brundage RC; Manion D; Ruiz N; Gersten M; Becker M; McNamara J; Mofenson LM; Purdue L; Siminski S; Graham B; Kornhauser DM; Fiske W; Vincent C; Lischner HW; Dankner WM; Flynn PM
    N Engl J Med; 1999 Dec; 341(25):1874-81. PubMed ID: 10601506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study.
    Nieuwkerk PT; Sprangers MA; Burger DM; Hoetelmans RM; Hugen PW; Danner SA; van Der Ende ME; Schneider MM; Schrey G; Meenhorst PL; Sprenger HG; Kauffmann RH; Jambroes M; Chesney MA; de Wolf F; Lange JM;
    Arch Intern Med; 2001 Sep; 161(16):1962-8. PubMed ID: 11525698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team.
    Nachman SA; Stanley K; Yogev R; Pelton S; Wiznia A; Lee S; Mofenson L; Fiscus S; Rathore M; Jimenez E; Borkowsky W; Pitt J; Smith ME; Wells B; McIntosh K
    JAMA; 2000 Jan; 283(4):492-8. PubMed ID: 10659875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study).
    Pellegrin I; Breilh D; Montestruc F; Caumont A; Garrigue I; Morlat P; Le Camus C; Saux MC; Fleury HJ; Pellegrin JL
    AIDS; 2002 Jul; 16(10):1331-40. PubMed ID: 12131209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children.
    Saitoh A; Hsia K; Fenton T; Powell CA; Christopherson C; Fletcher CV; Starr SE; Spector SA
    J Infect Dis; 2002 May; 185(10):1409-16. PubMed ID: 11992275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in durability of treatment with initial PI-based regimens.
    Pérez-Elías MJ; Moreno A; Moreno S; Antela A; Dronda F; Muñoz V; Casado JL; Quereda C; Lopez D; Navas E
    HIV Clin Trials; 2003; 4(6):391-9. PubMed ID: 14628282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate.
    Krogstad P; Wiznia A; Luzuriaga K; Dankner W; Nielsen K; Gersten M; Kerr B; Hendricks A; Boczany B; Rosenberg M; Jung D; Spector SA; Bryson Y
    Clin Infect Dis; 1999 May; 28(5):1109-18. PubMed ID: 10452644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial--PACTG 377. Pediatric AIDS Clinical Trials Group 377 Study Team.
    Wiznia A; Stanley K; Krogstad P; Johnson G; Lee S; McNamara J; Moye J; Jackson JB; Mendez H; Aguayo R; Dieudonne A; Kovacs A; Bamji M; Abrams E; Rana S; Sever J; Nachman S
    AIDS Res Hum Retroviruses; 2000 Aug; 16(12):1113-21. PubMed ID: 10954886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virologic response of nine therapy-experienced children receiving 64 weeks of nelfinavir salvage therapy.
    Vavro CL; Zimmermann AM; McClernon DR; Kehne SL; Martel LA; Valentine ME; McKinney RE
    Ann N Y Acad Sci; 2000 Nov; 918():381-5. PubMed ID: 11131731
    [No Abstract]   [Full Text] [Related]  

  • 18. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of nelfinavir in patients switched from ritonavir/saquinavir combination antiretroviral therapy.
    Hellinger JA; Cohen CJ; Stein AJ; Gallant JE; Gathe J; Keiser P
    HIV Clin Trials; 2000; 1(2):25-8. PubMed ID: 11590495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children.
    Saitoh A; Singh KK; Powell CA; Fenton T; Fletcher CV; Brundage R; Starr S; Spector SA
    AIDS; 2005 Mar; 19(4):371-80. PubMed ID: 15750390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.